Immix Biopharma, Inc.
IMMX
$4.15
$0.184.53%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.37% | 10.77% | 15.65% | 58.80% | 21.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.62% | 42.85% | -16.23% | -7.23% | 63.47% |
| Operating Income | -3.62% | -42.85% | 16.23% | 7.23% | -63.47% |
| Income Before Tax | -6.16% | -50.46% | 14.83% | 6.72% | -64.59% |
| Income Tax Expenses | -30.63% | -13.59% | 11.36% | 33.33% | 63.24% |
| Earnings from Continuing Operations | -6.10% | -50.31% | 14.79% | 6.66% | -64.58% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -100.00% | -- |
| Net Income | -6.10% | -50.76% | 13.62% | 5.45% | -67.01% |
| EBIT | -3.62% | -42.85% | 16.23% | 7.23% | -63.47% |
| EBITDA | -2.38% | -41.73% | 16.87% | 7.56% | -63.40% |
| EPS Basic | 2.22% | -44.76% | 31.86% | 30.34% | -5.47% |
| Normalized Basic EPS | 2.18% | -45.16% | 31.27% | 29.85% | -6.39% |
| EPS Diluted | 2.22% | -44.76% | 31.86% | 30.34% | -5.47% |
| Normalized Diluted EPS | 2.18% | -45.16% | 31.27% | 29.85% | -6.39% |
| Average Basic Shares Outstanding | 8.50% | 4.16% | 26.72% | 35.73% | 58.38% |
| Average Diluted Shares Outstanding | 8.50% | 4.16% | 26.72% | 35.73% | 58.38% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |